drugset
Drugs / Group B Meningococcal 44/76 MOS NOMV 5D Vaccine
last change Dec 2007 re-read 3 minutes ago

Group B Meningococcal 44/76 MOS NOMV 5D Vaccine

Vaccine

Developed for
meningococcal meningitis
Investigated by
U.S. Army Medical Research and Development Command · Walter Reed Army Institute of Research (WRAIR)

Trials 1

today NCT00248833 · Ph 1
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00248833 Dec 2005 → Nov 2006 meningococcal meningitis U.S. Army Medical Research and Development Command Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Group B Meningococcal 44/76 MOS NOMV 5D Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00248833 ↗
Modality Vaccine “The purpose of this study is to determine if the vaccine called Group B Meningococcal 44/76 MOS NOMV 5D Vaccine is safe and free from side effects” NCT00248833 ↗
Route Intramuscular “Vaccinations were given intramuscularly at 0, 6, and 24 weeks.” NCT00248833 ↗